Filling the need for trusted information on national health issues…

Trending on kff Medicare & Medicaid at 50 Individual Market Medicaid Expansion

Kaiser Daily Global Health Policy ReportDrug Resistance Search Results « » The Henry J. Kaiser Family Foundation

Drug Resistance

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Survey Finds 1 In 10 New Cases Of TB In China Are Drug-Resistant

“One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic,” the Associated Press reports (Wong, 6/7). “‘In 2007, one third of the patients with new cases of tuberculosis and one half of the patients with previously treated tuberculosis had drug-resistant disease,’ said the study in the New England Journal of Medicine,” Agence France-Presse reports, adding, “Even more, the prevalence of multi-drug resistant [tuberculosis (MDR-TB)] in new cases (5.7 percent) was nearly twice the global average, said the study” (6/6).

Experimental Drug Tested Against Multi-Drug Resistant TB

“Researchers who tested a novel type of antibiotic against multi-drug-resistant tuberculosis [MDR-TB] are reporting that nearly half of patients who got the new drug cleared the bacteria from their lung fluid in two months,” according to a study published Thursday in the New England Journal of Medicine, Reuters reports. Japanese pharmaceutical company Otsuka developed the experimental drug, delamanid, and “also designed and financed the clinical trial, which took place in 17 medical centers across nine countries,” the news service writes (Emery, 6/6).

WHO Warns Of Drug-Resistant Strains Of Gonorrhea

“Drug-resistant strains of gonorrhea have spread to countries across the world, the U.N. health agency said on Wednesday, and millions of patients may run out of treatment options unless doctors catch and treat cases earlier,” Reuters reports (Kelland, 6/6). “Already several countries, including Australia, France, Japan, Norway, Sweden and the United Kingdom are reporting cases of resistance to cephalosporin antibiotics — the last treatment option against gonorrhea,” a WHO press release states (6/6).

State Department Working To Combat Counterfeit Drugs

“Counterfeit, falsified, and substandard drugs are a dangerous threat to people around the world, including Americans,” therefore “we have a vital interest in ensuring the safety of an ever more complex global drug supply chain,” Jennifer White, a foreign service officer in the Office of International Health and Biodefense in the Bureau of Oceans and International Environmental and Scientific Affairs, writes in a post in the State Department’s “DipNote” blog. She notes that the “Department of State engages in the fight against counterfeit medicines using a multi-faceted approach,” including training foreign drug regulators; funding consumer outreach to raise awareness of the problem; being active in international bodies that address counterfeiting, such as the WHO; and “work[ing] in partnership with other U.S. government agencies, the health care community, patients, civil society, and the pharmaceutical industry to ensure that patients receive safe medicines and that those who put patients’ lives at risk can be prosecuted” (5/22).

Study Shows Prevalence Of Drug-Resistant HIV Strains In Uganda Rising, Among Highest In Sub-Saharan Africa

“The prevalence of drug-resistant HIV strains in Uganda has risen from 8.6 percent to 12 percent in the last five years, one of the highest rates in sub-Saharan Africa, according to a recent study,” PlusNews reports. “The PharmAccess African Studies to Evaluate Resistance (PASER) monitoring cohort study report for 2008-2012” — “which was based on results from the capital, Kampala, the western town of Fort Portal, and the eastern town of Mbale” — “found that the prevalence of transmitted drug resistance among people who have never taken life-prolonging antiretroviral (ARV) medication was substantially higher in Uganda” than in Kenya, Nigeria, South Africa, Zambia, and Zimbabwe, the news service writes.

Fake, Substandard Malaria Drugs Threatening Gains Made In Fight Against Disease, NIH Study Warns

“Low-quality and fake anti-malarial drugs flooding into markets in Asia and Africa are driving drug resistance and threatening gains made in the fight against the disease in the past decade, according to a study” conducted by researchers at the National Institutes of Health (NIH) and published Monday in the journal Lancet Infectious Diseases, Reuters reports (Kelland, 5/21). In an analysis of “27 sets of tests of antimalarial drugs purchased in Southeast Asia and Africa between 1999 and 2010,” “[a]bout a third of the drug samples from both continents failed,” the New York Times writes, noting, “Some were clearly criminal counterfeits, some were expired drugs that had been repackaged and some were poorly made with too little active ingredient” (McNeil, 5/21).

Globe And Mail Examines Resurgence Of Malaria In Congo

The Globe and Mail reports on “a massive resurgence of malaria [in the Democratic Republic of the Congo] that has baffled scientists and raised doubts about the global fight against the deadly scourge.” “Malaria is already the single biggest killer in Congo, with nearly 200,000 people dying annually, and now the trend is worsening,” the newspaper writes, noting that “the number of malaria patients has soared by a stunning 250 percent … since 2009,” according to data from Medecins Sans Frontieres (MSF).

Potential Public-Private Partnership Aims To Bring TB Vaccine Trials To Mines Of Southern Africa

GlobalPost’s “Global Pulse” blog reports on a potential public-private partnership that aims to bring tuberculosis (TB) vaccine trials to the gold mines of Southern Africa, where, “[f]or every 100,000 workers …, 3,000 have tuberculosis, and many have often-fatal, drug-resistant strains of TB.” The blog writes that mining company “Anglo American announced Tuesday at the GBCHealth Conference [in New York] that it has agreed in principle to make its mines available for TB vaccine trials organized by Aeras, a non-profit that has 12 TB vaccine candidates now in various stages of research,” noting, “No formal agreement has been reached, but Anglo American’s spokesman vowed to make it happen.”

Immediate Response Required To Curb Spread Of Artemisinin-Resistant Malaria In Burma

In this Wall Street Journal opinion piece, Jay Winsten, associate dean at the Harvard School of Public Health, and Trish Stroman, a principal at the Boston Consulting Group, examine “the emergence in Southeast Asia of malarial parasites resistant to artemisinin — the current gold-standard drug for treating the disease,” writing it “poses grave new challenges.” Winsten and Stroman recount a brief history of artemisinin resistance in the region and note, “While many affected countries in the region are taking swift countermeasures, the situation remains serious in Burma,” also known as Myanmar.

Insecticide Resistance Threatens Malaria Control Efforts, WHO Warns

“Malaria-carrying mosquitoes in Africa and India are becoming resistant to insecticides, putting millions of lives at greater risk and threatening eradication efforts, health experts said on Tuesday,” Reuters reports (Kelland, 5/15). Experts fear resistance “could reverse the recent drop in malaria mortality credited to insecticide spraying in the home and coating of bed nets, which save about 220,000 children’s lives each year, according to the WHO,” Nature writes, adding, “Insecticide resistance could also result in as many as 26 million further cases a year, the organization predicts, costing an extra $30 million to $60 million annually for tests and medicines” (Maxmen, 5/15).